RECRUITING

Digital Measures for Clinical Trial Endpoints in Huntington's Disease

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

MEND-HD is a longitudinal study evaluating the feasibility of passive monitoring of gait and chorea in patients with HD and the meaningfulness of these outcomes for patients with HD and their care partners/support persons. Participants will take part in four virtual visits with study investigators to answer survey questions on movement and cognition, perform in-home movement assessments, and take part in an interview regarding the meaningfulness of gait and chorea in their daily lives. Participant and care partner interviews will be used for symptom mapping and qualitative data analysis to assess the relevance and impact of the targeted symptoms on the participant's daily life.

Official Title

Digital Measures for Clinical Trial Endpoints in Huntington's Disease (MEND-HD)

Quick Facts

Study Start:2025-06-20
Study Completion:2026-09-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07010705

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:25 Years to 60 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Inclusion Criteria for participants with adult-onset HD:
  2. * Age of 25-60 years.
  3. * Genetically confirmed HD (HD-ISS Stage 2 or early Stage 3)
  4. * English speaking.
  5. * Age of 25-60 years.
  6. * English speaking.
  7. * Self-identified support person or family member of the enrolled participants with HD.
  8. * 18 years or older
  9. * English speaking.
  1. * Diagnosis of juvenile-onset HD.
  2. * History of co-morbid neurological disease or disorders such as stroke, multiple sclerosis, or moderate to severe
  3. * Traumatic Brain Injury.
  4. * Use of an assistive device for ambulation.
  5. * Montreal Cognitive Assessment (MoCA) score of 18 or lower
  6. * Acute or chronic medical conditions that significantly impact gait or mobility in the opinion of the investigator, e.g. ankle sprain or fracture, or any orthopedic,
  7. * cardiovascular or psychiatric disease.
  8. * Pregnancy
  9. * Cannot be enrolled into a blinded intervention trial at Baseline

Contacts and Locations

Study Contact

Sugitha Maheswaran, BS
CONTACT
5857040344
Sugi.Mahes@chet.rochester.edu

Study Locations (Sites)

University of Rochester Medical Center
Rochester, New York, 14642
United States

Collaborators and Investigators

Sponsor: University of Rochester

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-06-20
Study Completion Date2026-09-30

Study Record Updates

Study Start Date2025-06-20
Study Completion Date2026-09-30

Terms related to this study

Keywords Provided by Researchers

  • Huntington Disease

Additional Relevant MeSH Terms

  • Huntington Disease
  • Healthy